Analysis of Complement Activation and Regulation by Mass Cytometry
通过质谱流式细胞术分析补体激活和调节
基本信息
- 批准号:9235239
- 负责人:
- 金额:$ 20.51万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-03-15 至 2019-02-28
- 项目状态:已结题
- 来源:
- 关键词:AddressAdjuvantAge related macular degenerationAlpha CellAnaphylatoxinsAntibodiesAntibody FormationAntigen-Antibody ComplexAutoimmunityB-Cell ActivationBinding ProteinsCD4 Positive T LymphocytesCell DeathCell Differentiation processCell LineCell SurvivalCellsClinicalCollectionComplementComplement 3 ConvertaseComplement ActivationComplement Membrane Attack ComplexComputer softwareCytolysisCytometryDangerousnessDevelopmentDiagnosticDiseaseDisease ProgressionEffector CellEmerging TechnologiesEpithelial CellsFailureFeedbackFlow CytometryGenerationsGenomicsGoalsHeavy MetalsHemolytic-Uremic SyndromeHumanImmune systemIndividualInfectious AgentInflammatoryInflammatory ResponseInjuryInstructionInvestigationIsotope LabelingIsotopesLupusMass Spectrum AnalysisMeasuresMediatingMembraneMethodsNatureOnset of illnessOpsoninPathway interactionsPhenotypePlayProteinsReagentRecruitment ActivityRegulationReporterResistanceRoleSignal TransductionSiteStructure of retinal pigment epitheliumSurfaceT-LymphocyteTherapeutic AgentsTherapeutic InterventionTimeTissuesWorkantibody conjugatebasecell typedesignhuman diseaseimmune clearanceinflammatory milieumembrane assemblynew technologynovelnovel diagnosticsnovel therapeutic interventionpathogenpublic health relevanceresponsetool
项目摘要
DESCRIPTION (provided by applicant): Analysis of complement activation and regulation by mass cytometry SUMMARY Complement (C) is a collection of 50-60 soluble and membrane-bound proteins that constitutes the first line of defense of the intravascular space. Complement marks infectious agents for immune clearance or lysis, promotes the local inflammatory response, and facilitates B cell activation and antibody production (i.e. nature's adjuvant) as wel as T cell effector responses. Complement is also a principal cause of tissue damage: Complement-related disease and injury states can be traced to inappropriate complement activation (humoral autoimmunity), inadequate complement regulation (PNH, atypical hemolytic uremic syndrome, age-related macular degeneration), or a failure to effectively clear immune-complexes and/or cell debris (lupus). Therapeutic agents have begun to emerge in the clinical setting to inhibit systemic complement activity. The three complement activation pathways converge with the assembly of C3 convertases on a target surface. C3 convertase generates opsonins that promote target clearance, release anaphylatoxins that activate and recruit inflammatory cells, initiate the assembly of the membrane attack complex (MAC, C5b-9), and, importantly, engage a positive feedback mechanism that amplifies all of these activities. The MAC forms a pore that compromises membrane integrity and commonly leads to pathogen lysis. Host cells are protected from complement activity by surface regulators that inhibit convertase formation, compromise convertase stability and obstruct MAC assembly and function. Nucleated cells respond to complement attack by engaging intracellular pathways that further determine cell survival, cell differentiation or cell death. Mass cytometry (MC) is an emerging technology that provides the unique ability to measure >40 proteins on a single cell basis. We propose to use MC to profile the complement activators, regulators, and intracellular responses as a cell undergoes complement attack. We have selected two vastly different cell types of translational significance for hypothesis driven analyses, retinal pigment epithelial (RPE) cells and T cells, and propose the following Specific Aims: 1. To construct and validate a panel of complement-specific heavy isotope-labeled reporter antibodies; 2. To profile by mass cytometry the responses of a human RPE cell line to sublytic C attack, and compare to those findings to the responses of other epithelial cell types; 3. To profile by mass cytometry the responses of CD4+ T cells undergoing C activation. We anticipate the proposed work will generate a set of novel, unique and critical tools to delineate in unprecedented detail the activation and regulation of complement at the membrane and intracellular levels and to define the impact that intracellular responses play on comlement-dependent disease. Further, the reagents/methods we propose to generate/establish will facilitate the development of a new generation of C-based diagnostics in subsequent investigations and likely drive a paradigm shift in C-based therapeutic intervention.
描述(由申请人提供):通过质谱流式细胞术分析补体激活和调节概要补体(C)是50-60种可溶性膜结合蛋白的集合,构成血管内空间的第一道防线。补体标记感染因子以进行免疫清除或裂解,促进局部炎症反应,并促进 B 细胞活化和抗体产生(即天然佐剂)以及 T 细胞效应反应。补体也是组织损伤的主要原因:补体相关疾病和损伤状态可归因于补体激活不当(体液自身免疫)、补体调节不足(PNH、非典型溶血性尿毒症综合征、年龄相关性黄斑变性)或未能有效清除免疫复合物和/或细胞碎片(狼疮)。临床上已经开始出现抑制全身补体活性的治疗药物。 三种补体激活途径与 C3 转化酶在靶标表面的组装汇聚在一起。 C3 转化酶产生调理素,促进靶标清除,释放过敏毒素,激活和募集炎症细胞,启动膜攻击复合物(MAC、C5b-9)的组装,并且重要的是,参与放大所有这些活动的正反馈机制。 MAC 形成的孔会损害膜的完整性,通常会导致病原体裂解。表面调节剂可抑制转化酶的形成、损害转化酶的稳定性并阻碍 MAC 的组装和功能,从而保护宿主细胞免受补体活性的影响。有核细胞通过参与细胞内途径来响应补体攻击,进一步决定细胞存活、细胞分化或细胞死亡。 质谱流式细胞术 (MC) 是一项新兴技术,具有在单细胞基础上测量 > 40 种蛋白质的独特能力。我们建议使用 MC 来分析细胞受到补体攻击时的补体激活剂、调节剂和细胞内反应。我们选择了两种对于假设驱动分析具有翻译意义的截然不同的细胞类型:视网膜色素上皮 (RPE) 细胞和 T 细胞,并提出以下具体目标: 1. 构建并验证一组补体特异性重同位素标记的报告抗体; 2. 通过质谱流式分析分析人 RPE 细胞系对亚裂解 C 攻击的反应,并将这些结果与其他上皮细胞类型的反应进行比较; 3. 通过质谱流式分析来分析经历 C 激活的 CD4+ T 细胞的反应。 我们预计拟议的工作将产生一套新颖、独特和关键的工具,以前所未有的细节描述补体在膜和细胞内水平的激活和调节,并确定细胞内反应对补体依赖性疾病的影响。此外,我们建议生成/建立的试剂/方法将有助于在后续研究中开发新一代基于 C 的诊断方法,并可能推动基于 C 的治疗干预的范式转变。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DENNIS EMIL HOURCADE其他文献
DENNIS EMIL HOURCADE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DENNIS EMIL HOURCADE', 18)}}的其他基金
Cellular Models of a Monogenic Small Vessel Disease of the Brain
脑单基因小血管疾病的细胞模型
- 批准号:
10307638 - 财政年份:2020
- 资助金额:
$ 20.51万 - 项目类别:
Characterization/bioinformatics-modeling of nanoparticle:complement interactions
纳米粒子的表征/生物信息学建模:补体相互作用
- 批准号:
8323416 - 财政年份:2010
- 资助金额:
$ 20.51万 - 项目类别:
Characterization/bioinformatics-modeling of nanoparticle:complement interactions
纳米粒子的表征/生物信息学建模:补体相互作用
- 批准号:
8068114 - 财政年份:2010
- 资助金额:
$ 20.51万 - 项目类别:
Characterization/bioinformatics-modeling of nanoparticle:complement interactions
纳米粒子的表征/生物信息学建模:补体相互作用
- 批准号:
8150949 - 财政年份:2010
- 资助金额:
$ 20.51万 - 项目类别:
Complement Convertase: Assembly, Function and Regulation
补体转化酶:组装、功能和调节
- 批准号:
8070077 - 财政年份:2010
- 资助金额:
$ 20.51万 - 项目类别:
Complement Convertase: Assembly, Function and Regulation
补体转化酶:组装、功能和调节
- 批准号:
6616462 - 财政年份:2003
- 资助金额:
$ 20.51万 - 项目类别:
Complement Convertase: Assembly, Function and Regulation
补体转化酶:组装、功能和调节
- 批准号:
7800882 - 财政年份:2003
- 资助金额:
$ 20.51万 - 项目类别:
COMPLEMENT CONVERTASE: ASSEMBLY, FUNCTION AND REGULATION
补充转化酶:组装、功能和调节
- 批准号:
8437634 - 财政年份:2003
- 资助金额:
$ 20.51万 - 项目类别:
COMPLEMENT CONVERTASE: ASSEMBLY, FUNCTION AND REGULATION
补充转化酶:组装、功能和调节
- 批准号:
8897952 - 财政年份:2003
- 资助金额:
$ 20.51万 - 项目类别:
Complement Convertase: Assembly, Function and Regulation
补体转化酶:组装、功能和调节
- 批准号:
8055493 - 财政年份:2003
- 资助金额:
$ 20.51万 - 项目类别:
相似海外基金
Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
- 批准号:
23K08213 - 财政年份:2023
- 资助金额:
$ 20.51万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
- 批准号:
2881726 - 财政年份:2023
- 资助金额:
$ 20.51万 - 项目类别:
Studentship
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
- 批准号:
10735090 - 财政年份:2023
- 资助金额:
$ 20.51万 - 项目类别:
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
- 批准号:
10722146 - 财政年份:2023
- 资助金额:
$ 20.51万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 20.51万 - 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
- 批准号:
10935776 - 财政年份:2023
- 资助金额:
$ 20.51万 - 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
- 批准号:
10935796 - 财政年份:2023
- 资助金额:
$ 20.51万 - 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
- 批准号:
10935775 - 财政年份:2023
- 资助金额:
$ 20.51万 - 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
- 批准号:
10649041 - 财政年份:2023
- 资助金额:
$ 20.51万 - 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
- 批准号:
10735964 - 财政年份:2023
- 资助金额:
$ 20.51万 - 项目类别: